Founded in 2015 by Nobel Laureate Professor Barry J. Marshall, who was awarded the Nobel Prize for his groundbreaking discovery of Helicobacter pylori, Shenzhen Hongmed-Infagen Co., LTD. is a high-tech enterprise dedicated to revolutionising the diagnosis and treatment of gastrointestinal diseases. The company primarily focuses on conditions associated with Helicobacter pylori, developing personalised treatment strategies for multi-drug resistant strains. Concurrently, Hongmed-Infagen is advancing novel products for intestinal cancer screening and prevention, including diagnostics for Calprotectin and Pancreatic Elastase-1.

Located in Shenzhen, the company's facilities span approximately 3,000 square meters, featuring modern offices, a 500-square-meter state-of-the-art R&D laboratory, and a 1,000-square-meter GMP-certified manufacturing space. Under Professor Marshall's expert guidance, Hongmed-Infagen's core mission is to lead the field in the precision diagnosis and treatment of gastrointestinal cancer, with the vision of becoming a world-class biomedical high-end manufacturing leader.